Article

FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancer

2025-05-29

Abstract excerpt

<title>Abstract</title> <p>Purpose Resistance to HER2-targeted therapies remains a major clinical challenge in metastatic breast cancer (MBC), with limited biomarkers to guide treatment. This study sought to evaluate the prognostic and therapeutic significance of FGFR amplification in patients with HER2-expressing MBC treated with HER2-targeted therapies. Methods We retrospectively analyzed 73 patients with HER...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bf38b5ec-1da9-515e-8ff8-060159ba56fd
DOI: 10.21203/rs.3.rs-6641146/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancerDOI 10.21203/rs.3.rs-6641146/v1Read

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancerSemantic proximity Read

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerSemantic proximity Read

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Semantic proximity Read

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Semantic proximity Read

FGFR rearrangements: oncogenic drivers and therapeutic targets.Semantic proximity Read

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancerSemantic proximity Read

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Semantic proximity Read

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read

FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic diseaseSemantic proximity Read

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.Semantic proximity Read